Lannett Hits A High After Loss Of Levothyroxine

Company Plans To Launch Several New Products By End Of June

Despite reporting a 16.4% drop in turnover in its financial third quarter, Lannett says it has recorded the highest quarterly sales since a key levothyroxine distribution deal fell apart last year. The company has launched 14 products in the financial year so far and plans to launch several more.

Coming_Soon
Lannett’s pipeline has 20 products in development and 17 pending ANDAs • Source: Shutterstock

Lannett says it is satisfied with its reported sales of $144.4m for the third quarter of its financial year ending in June 2020, despite this representing a 16.4% drop compared to the $172.8m reported for the third quarter of fiscal 2019.

CEO Tim Crew explained that after losing the distribution deal for highly profitable thyroid drug levothyroxine – when former partner...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Strategy

More from Business